Kids' Chance of Indiana 2020
1 MIN READ
Aside from being a National Partner of Kids’ Chance, Genex team members like Jane Shea are actively involved in supporting the organization on the state level. Watch this video as Jane and her peers explain how your efforts make a difference for Kids’ Chance recipients in Indiana.
Kids' Chance of Indiana 2020
1 MIN READ
Aside from being a National Partner of Kids’ Chance, Genex team members like Jane Shea are actively involved in supporting the organization on the state level.
Prescription and Private Label Topical Trends in 2019
1 MIN READ
These and other challenges call for careful oversight that includes identification, clinical review and intervention, and/or recommendation of therapeutic alternatives where appropriate to help control inappropriate utilization and spend.
At the eye of the storm: An opioid overdose epidemic and a viral pandemic converge
2 MIN READ
s 2020 opened, a persistent and tragic opioid overdose epidemic was near the front of a list of national concerns in the US. Some 20+ million Americans are reported to have a substance use disorder and 2M of those misuse opioids.
Is Your Workplace Safe2Work?
As employers are looking for efficient ways to keep work environments safe from COVID-19, Optis has developed Safe2Work, an app-enabled, web-based health screening program designed to help stop the
Quality Control in Clinical, Interview with Sharon Riley
2 MIN READ
We interviewed Sharon Riley, Director of Service Operations for Field Case Management, Coventry about best practices for quality assurance within a clinical case management program. Read on for her insightful responses.
Opioid Risk Mitigation: Medication-Assisted Treatment (MAT) and Naloxone
2 MIN READ
This week in our in-depth review of our Coventry Drug Trends series, part three, we focus on opioid risk mitigation strategies. While opioids continue to decline in workers’ compensation as both a percentage of total script volume and costs, it remains vital to promote evidence-based strategies such as MAT and naloxone to curb opioid issues.